| Company/Division name | LGM Pharma |
| Parent company | LGM Pharma |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 9 |
| City reshored to: | Colorado Springs |
| State(s) reshored to: | CO |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceutical drugs |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Higher productivity, Manufacturing/engineering joint innovation (R&D) |
